» Articles » PMID: 19126579

The Role of IGF-1R in Pediatric Malignancies

Overview
Journal Oncologist
Specialty Oncology
Date 2009 Jan 8
PMID 19126579
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

The insulin-like growth factor (IGF) family consists of ligands (IGF-I, IGF-II, insulin), several receptors (including IGF-1R), and six binding proteins (IGFBP-1 through IGFBP-6). Members of this family regulate key cellular activities and they also play an important role in the development and progression of both adult and childhood cancers. Binding of a ligand to the receptor leads to its activation, followed by signal transduction along several pathways. In some childhood malignancies, IGF-1R can be activated by endocrine, autocrine, or paracrine mechanisms. Although mutations in IGF-1R have not been identified, this signaling pathway is upregulated in many childhood cancers. These findings have led to the development of a host of IGF-1R signaling modulators that are currently being tested in clinical trials. This review explores the role of IGF-1R in a range of childhood malignancies.

Citing Articles

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.

Qi Y, Deng S, Wang K Am J Cancer Res. 2024; 14(9):4172-4196.

PMID: 39417188 PMC: 11477839. DOI: 10.62347/KIVS3169.


Modern treatment strategies in pediatric oncology and hematology.

Adamczewska-Wawrzynowicz K, Wiacek A, Kozlowska A, Mikosza K, Szefler L, Dudlik W Discov Oncol. 2023; 14(1):98.

PMID: 37314524 PMC: 10267092. DOI: 10.1007/s12672-023-00658-7.


The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.

Hebron K, Wan X, Roth J, Liewehr D, Sealover N, Frye W Clin Cancer Res. 2022; 29(2):472-487.

PMID: 36322002 PMC: 9852065. DOI: 10.1158/1078-0432.CCR-22-1646.


Mini Review: Molecular Interpretation of the IGF/IGF-1R Axis in Cancer Treatment and Stem Cells-Based Therapy in Regenerative Medicine.

Lin S, Lin C, Lee W, Teng C, Shyu W, Jeng L Int J Mol Sci. 2022; 23(19).

PMID: 36233084 PMC: 9570316. DOI: 10.3390/ijms231911781.


An insulin growth factor-I/II-neutralizing monoclonal antibody in combination with epidermal growth factor receptor inhibitors potently inhibits tumor cell growth.

Ma G, Tan C, Shan Y, Shao N, Wang F, Dimitrov D J Cancer. 2022; 13(6):1830-1836.

PMID: 35399718 PMC: 8990425. DOI: 10.7150/jca.69064.


References
1.
Yin D, Vreeland F, Schaaf L, Millham R, Duncan B, Sharma A . Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res. 2007; 13(3):1000-9. DOI: 10.1158/1078-0432.CCR-06-1910. View

2.
Toretsky J, Steinberg S, Thakar M, Counts D, Pironis B, Parente C . Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer. 2001; 92(11):2941-7. DOI: 10.1002/1097-0142(20011201)92:11<2941::aid-cncr10072>3.0.co;2-c. View

3.
Butler A, Yakar S, Gewolb I, Karas M, Okubo Y, LeRoith D . Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol. 1999; 121(1):19-26. DOI: 10.1016/s0305-0491(98)10106-2. View

4.
Romanus J, Helman L, Cooper M, Rechler M, Israel M . Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J Clin Invest. 1989; 84(3):829-39. PMC: 329726. DOI: 10.1172/JCI114243. View

5.
Scotlandi K, Benini S, Nanni P, Lollini P, Nicoletti G, Landuzzi L . Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998; 58(18):4127-31. View